---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-000338"
form_type: "8-K"
ticker: "RARE"
cik: "0001515673"
company_name: "Ultragenyx Pharmaceutical Inc."
filed_at: "2023-01-06T23:59:59+00:00"
generated_at: "2026-06-20T18:44:30.234866+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Ultragenyx reports preliminary 2022 revenue $352-$356M; guides 2023 revenue $425-$450M

## Summary
- Preliminary 2022 total product revenue $352M-$356M; Crysvita territories $257M-$258M; Dojolvi $55M-$56M.
- 2023 revenue guidance $425M-$450M; Crysvita $325M-$340M; Dojolvi $65M-$75M; net cash used ops <$400M.
- Year-end 2022 cash ~$900M; non-recurring items included $90M capex, $75M GeneTx acquisition, $30M Evkeeza license.
- Pipeline: UX143 Phase 2 data mid-2023; DTX301 Phase 3 start Q1 2023; UX701 Stage 1 enrollment mid-2023; DTX401 Phase 3 data H1 2024.
- Crysvita guidance reflects 20% YoY growth; royalties from Europe and North America (starting April 2023) included.

## SEC filing metadata
- accession: 0000950170-23-000338
- form_type: 8-K
- ticker: RARE
- cik: 0001515673
- company_name: Ultragenyx Pharmaceutical Inc.
- filed_at: 2023-01-06T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1515673/000095017023000338/0000950170-23-000338-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1515673/000095017023000338/rare-20230106.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-000338
- JSON: https://secwatch.observer/filing/0000950170-23-000338.json
- Plain text: https://secwatch.observer/filing/0000950170-23-000338.txt

## Key facts
- Earnings Releases
  Ultragenyx Pharmaceutical Inc. reported 2023 results: revenue $425 million to $450 million. Guidance initiated.
  - Period: 2023
  - Revenue: $425 million to $450 million
  - Guidance: initiated
  - Result: guidance update
  source text: 2023 expected Total Product Revenue guidance between $425 million to $450 million
  evidence_url: https://www.sec.gov/Archives/edgar/data/1515673/000095017023000338/0000950170-23-000338-index.htm
- Earnings Releases
  Ultragenyx Pharmaceutical Inc. reported fiscal year 2022 results: revenue $352 million to $356 million.
  - Period: fiscal year 2022
  - Revenue: $352 million to $356 million
  - Result: preliminary results
  source text: Preliminary 2022 Total Product Revenue of $352 million to $356 million
  evidence_url: https://www.sec.gov/Archives/edgar/data/1515673/000095017023000338/0000950170-23-000338-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.